bitop AG receives Frost & Sullivan’s 2013 New Product Innovation Award for its Ectoin Allergy products

24-Jun-2013 - Germany

Frost & Sullivan grants the 2013 European New Product Innovation Award in Extremolytes Therapeutics to bitop AG. The benchmark by Frost & Sullivan indicates that bitop AG has made available ectoin, one of the most commonly found extremolytes in nature, for human use.

bitop AG has explored and validated
Ectoin as a naturally-derived ingredient to alleviate and treat symptoms of allergic diseases as allergic rhinitis or conjunctivitis. Additional benefits of Ectoin can be achieved in the treatment of atopic dermatitis, dryness of the mucosa in the nose and of the conjunctiva in the eye while suffering from sicca syndromes and the reduction of common symptoms of cough and cold.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...